Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Source: nct - Country: Hungary,Czech Republic,South Africa,Israel,United States,Argentina,Spain,France,Australia,Portugal
nct
Update Il y a 5 ans
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).
Country
Argentina
,
Australia
,
Belgium
,
Bosnia and Herzegovina
,
Bulgaria
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Portugal
,
Romania
,
Serbia
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death
The Primary objective was to assess the efficacy of Celivarone for the prevention of Implantable Cardioverter Defibrillator (ICD) interventions or death. Secondary objectives were: - To assess the tolerability and safety of the different dose regimens of Celivarone in the selected population. - To document Celivarone plasma levels during the study.
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
Chile
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Japan
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Turkey
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1